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Resistance-modifying agentsThe increasing occurrence of bacterial resistance to antibiotics has now reached a critical level. Finding
antibiotic coadjuvants capable to inhibit the bacterial resistance mechanisms would be a valuable mid-term
solution, until new classes of antibiotics are discovered. Selected plant alkaloids were combined with 5
antibiotics against 10 Staphylococcus aureus strains, including strains expressing distinct efﬂux pumps and
methicillin-resistant S. aureus strains. The efﬁcacy of each combination was assessed using the microdilution
checkerboard, time-kill, Etest, and disc diffusion methods. The cytotoxicity of the alkaloids was evaluated in a
mouse ﬁbroblast cell line. Potentiation was obtained in 6% of all 190 combinations, especially with the
combination of: ciproﬂoxacin with reserpine (RES), pyrrolidine (PYR), and quinine (QUIN); tetracycline with
RES; and erythromycin with PYR. The highest cytotoxicity values were found for QUIN (half maximal
inhibitory concentration [IC50] = 25 ± 2.2 mg/L) and theophylline (IC50 = 100 ± 4.7 mg/L).+351-225081449.© 2014 Elsevier Inc. All rights reserved.1. Introduction
The evolution of bacterial resistance increased over the last years,
and given the difﬁculty of new drug discovery by the traditional
methods, new strategies are urgently needed. The use of paired and
even triple combinations of antimicrobial drugs with positive in vitro
interactions has become increasingly important in clinical applica-
tions. The combinatorial therapy has also been a common practice in
order to prevent the emergence and widespread of multi-drug–
resistant (MDR) infections (Sopirala et al., 2010). Indeed, the
biological system is less able to compensate for the action of 2 or
more drugs simultaneously (Zimmermann et al., 2007). Also, the cost
of developing a new antimicrobial versus the cost of ﬁnding a
combination between known ones is an easy justiﬁcation for research
into drug potentiation (Lambert et al., 2003).
While several bioactive compounds have a signiﬁcant antimicro-
bial activity, other compounds have been found to be synergistic
enhancers of antibiotics, despite they may not have any antimicrobial
properties alone (Abreu et al., 2012b). Themodes of action underlying
the synergistic activity of these antibiotic adjuvants can be diverse.
Two important mechanisms include the serial or orthogonal inhibi-
tion of vital physiological pathways or the dispersion of a bioﬁlm toplanktonic cells, resulting in an increased susceptibility to antibiotics
(Kalan andWright, 2011). Also, several antibiotic adjuvants have been
evaluated for their action as resistance-modifying agents (RMAs)
(Hemaiswarya et al., 2008), i.e., compounds that can modify or inhibit
the bacterial mechanisms of resistance, so that antibiotics can
efﬁciently kill the resistant bacteria. Several RMAs were already
described (Chan et al., 2011; Gibbons et al., 2003; Khan et al., 2006;
Roccaro et al., 2004; Schmitz et al., 1998; Yam et al., 1998). Efﬂux
pump inhibitors (EPIs) are important examples of RMAs since they
can prevent the extrusion of an antibiotic to the exterior of the cell and
thus allow the antibiotic to act efﬁciently against bacteria. If such
compounds were clinically approved, many inefﬁcient and old
antibiotics (for which resistance mechanisms are already disseminat-
ed) could be recycled. Therefore, many of the current problems on the
lack of new antibiotics and new classes of antimicrobials would be
possible to solve.
It is unquestionable that natural compounds have been a major
source of new bioactive agents. In fact, natural compounds were
already “prescreened” over millions of years ago by natural selection,
which puts them ahead in the race for the discovery of new
antimicrobials. Plants have been traditionally used for centuries to
treat human diseases and inhibit microbial growth. They are
important sources of a wide variety of secondary metabolites such
as alkaloids, isothiocyanates, peptides, phenolics, polyacetilenes,
and terpenoids, which have been well-established to possess
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heterocyclic nitrogen compounds (Cowan, 1999). There is an
excellent rationale that plant alkaloids should possess antibacterial
activity, particularly given the number of cytotoxic drugs and
templates from this source (Gibbons, 2004).
The objective of this work was to determine whether several
alkaloids (caffeine [CAF], reserpine [RES], pyrrolidine [PYR], theoph-
ylline [THEO], and quinine [QUIN], Fig. 1) were able to improve the
activity of common antibiotics belonging to several classes (ampicillin
[AMP] and oxacillin [OXA] – β-lactams; ciproﬂoxacin [CIP] –
ﬂuoroquinolone; erythromycin [ERY] – macrolide; and tetracycline
[TET]). Several resistant strains of Staphylococcus aureuswere used. S.
aureus and, speciﬁcally, MRSA strains are important pathogens in
clinical settings, responsible for a high level of hospital-acquired
infections (Oluwatuyi et al., 2004), due to their great capacity of
acquiring resistance genes. The methods for detecting potentiation
used in this work were the broth microdilution checkerboard, time-
kill assay, Etest, and the disc diffusion method (DDM). A comparison
of the results of potentiation given by these 4 methods was evaluated.
2. Materials and methods
2.1. Bacterial strains
Three clinical MRSA (MJMC001, MJMC002, MJMC004) and 3
clinical MSSA (MJMC003, MJMC009, MJMC010) were isolated from
patients with diabetic feet at the Centro Hospitalar de Trás-os-Montes
e Alto Douro, EPE (Portugal). S. aureus SA1199B, which overexpresses
the NorAMDR efﬂux pump, S. aureus RN4220, which contains plasmid
pU5054 (that carries the gene encoding the MsrA macrolide efﬂux
protein), and S. aureus XU212, which possesses the TetK efﬂux pump
and is also an MRSA strain, were kindly provided by S. Gibbons
(University College London, UCL) (Gibbons and Udo, 2000; Gibbons
et al., 2003; Oluwatuyi et al., 2004; Smith et al., 2007). The collection
strain S. aureus CECT 976, already used as model microorganism for
antimicrobial tests with phytochemical compounds(Abreu et al.,
2012a; Saavedra et al., 2010; Simões et al., 2008), was included as
a quality control strain. Prior to use, each strain at −80 °C wasFig. 1. Chemical structures of thetransferred onto Mueller–Hinton (MH; Merck, Darmstadt, Germany)
agar plate, grown overnight, and inoculated into MH broth at 37 °C
and under agitation (150 rpm).
2.2. Antibiotics and alkaloids
AMP, CIP, ERY, OXA, and TET were obtained from Sigma (Portugal)
and prepared according to the manufacturer recommendations. CAF,
RES, PYR, THEO, and QUIN were purchased from Sigma and the stock
solutions were prepared in dimethyl sulfoxide (DMSO; Sigma, Sintra,
Portugal). Etest strips of the antibiotics (AB Biodisk, Solna, Sweden)
were obtained from Izasa (Portugal, Barcelona, Spain).
2.3. Antibacterial susceptibility testing
The MIC of each agent was determined by microdilution
techniques according to the Clinical and Laboratory Standards
Institute (CLSI) guidelines (NCCLS/CLSI, 2003). For S. aureus
SA1199B, RN4220, and XU212, only CIP, ERY, and TET were tested,
respectively. Bacteria (~106 CFU/mL) were inoculated into MH broth
and dispensed at 200 μL/well in 96-well microtiter plates, along with
2-fold dilutions of the compounds to test. Several intermediate
concentrations were also prepared in order to minimize the errors in
MIC determination. MIC was deﬁned as the lowest concentration of
the antimicrobial compound that inhibited bacterial growth after 24 h
of incubation at 37 °C. The bacterial growth was determined at 600
nm using a microplate reader (Spectramax M2e; Molecular Devices,
Inc., Sunnyvale, USA). Three independent experiments were per-
formed for each compound. The highest concentration of DMSO
remaining after dilution (10% (v/v)) caused no inhibition of bacterial
growth (data not shown).
2.4. Checkerboard microdilution assay
Checkerboard testing was performed in 96-well microtiter plates
in triplicate according to Chan et al. (2011) with some modiﬁcations.
After an overnight incubation into MH broth at 37 °C, bacterial
cultures were adjusted in fresh broth to approximately 106 CFU/mL.alkaloids used in this study.
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antibiotics and alkaloids (in a total volume of 200 μL) in different
concentrations so that each well contains the same amount of the
antibiotic, which is being 2-fold diluted along the x axis (rows), and
the same amount of the alkaloid being diluted on the y axis (columns).
Also, concentrations between the 2-fold dilutions range were
prepared. The antimicrobial solutions did not exceed 10% (v/v) of
the well. The concentration of each antibiotic tested ranged from 1/64
to 2 × MIC. The alkaloids were tested at several concentrations
ranging from 10 to 1000 mg/L, depending on the strain. Negative
growth controls were performed in a separate microtiter plate by
mixing sterile medium, without bacteria, with the alkaloids. Readings
were determined spectrophotometrically at 600 nm.2.5. Etest
Etest was only directed for the antibiotics, which achieved good
combinatorial results on the checkerboard and the disc diffusion
methods. This method was performed according to the manufac-
turer's instructions. Each alkaloid was added to MH agar (after
autoclaved and cooled) yielding the ﬁnal concentration desired,
which was chosen according to the checkerboard results. Then, the
medium was poured into 90 mm Petri dishes to give a uniform depth
of approximately 4 mm (~20 mL). The bacterial suspensions were
adjusted to 0.5 McFarland standards and seeded over hardened MH
agar Petri dishes using a sterilized cotton swab and allowed to set (for
10–15 min). Antibiotic Etest strips were applied in duplicate on the
MH agar plates. As control, the antibiotic strips were applied on
simple MH agar plates (without the alkaloid). Plates were incubated
for 24 h at 37 °C. The MICs were read on plates with the combination
of the 2 agents and on antibiotic control plates.2.6. Disc diffusion method
This was a modiﬁcation from the Kirby–Bauer method, and it was
already applied in other studies (Abreu et al., 2012a; Saavedra et al.,
2010). The bacterial inoculum and the MH agar plates were prepared
in the same way of that described for Etest. The concentration of the
alkaloids on the agar was chosen according to the checkerboard
results. Sterile blank discs (6-mm diameter; Oxoid, Oeiras, Portugal)
were placed on the agar plate seeded with the respective bacteria. A
volume of 15 μL of each antibiotic prepared according to the CLSI
guidelines (AMP – 10 μg/disc; CIP – 5 μg/disc; ERY – 15 μg/disc; TET –
30 μg/disc; and OXA – 1 μg/disc) (CLSI, 2003) was added to the blank
discs. Discs of antibiotics on simple MH agar plates (without the
alkaloid) were used as positive controls, and discs impregnated with
DMSO were used as negative controls. The plates were incubated at
37 °C for 24 h. After incubation, each inhibition zone diameter (IZD)
was recorded and analyzed according to CLSI guidelines (CLSI, 2003).
No inhibition zone was obtained with DMSO (data not shown). All
tests were performed in triplicate, and the antibacterial activity was
expressed as the mean of IZD (in mm).Table 1
Characterization of the effect promoted by a phytochemical in the activity of 1 antimicrobi
Interaction Checkerboard Etest
Potentiation MICa reduction N4-fold dilutions MICa reduction N3-fold diluti
Additive MICa reduction ≥2-fold and
b4-fold dilutions
MICa reduction ≥2-fold and
b3-fold dilutions
Negative MICa increase N4-fold dilutions MICa increase ≥3-fold dilutio
Indifferent interactions are considered between the limits proposed for additive and negati2.7. Time-kill assay
Time-kill studies were performed according to Roccaro et al.
(2004) with some modiﬁcations. This method was only performed
with strains SA1199B, RN4220, and XU212. Overnight cultures were
diluted with MH broth to a starting inoculum of 106 CFU/mL. Each
antibiotic was tested at MIC, ½ × MIC and ¼ × MIC. The concentra-
tion of the alkaloid was chosen according to the checkerboard results.
The combinations were added to sterilized 50 mL polystyrene capped
tubes and inoculated with each isolate in a total volume of 10 mL. The
antimicrobial combinations did not exceed 10% (v/v) of the ﬁnal
volume. Controls were performed with each compound separately.
The tubes were agitated in an orbital shaker (150 rpm) at 37 °C for 24
h. CFU counts in MH agar were performed after 0, 4, 8, and 24 h of the
beginning of the incubation. Before CFU counts, plates were incubated
at 37 °C for 18–24 h. The limit of detection was 50 CFU/mL.2.8. Classiﬁcation of a combination as negative/indifferent/additive/
potentiation
Positive interactions that intensify the potency of a bioactive
product are generally called potentiation. Additive and synergistic
effects are subsets of potentiation involved when this effect is
experimentally characterized and quantiﬁed. Negative interactions
(interferences) occur when certain components of the mixture inhibit
full biological activity of pharmacologically-active compounds by
reducing their stability or bioavailability or by enhancing their
metabolism (Lila and Raskin, 2005).
A new approach was developed for interactions between com-
pounds that have no antimicrobial activity but that can potentiate
antimicrobials. This approach is based on some synergistic deﬁnitions
applied for combinations involving 2 antimicrobials using checker-
board (Mackay et al., 2000; Rand et al., 1996), Etest(Cantón et al.,
2005; Lewis et al., 2002; Sopirala et al., 2010) and time-kill assay
(Eliopoulos and Eliopoulos, 1988; NCCLS/CLSI, 1999). Table 1 presents
the scheme proposed to classify an interaction as negative, indifferent,
additive, or potentiation.
In order to propose a classiﬁcation scheme for the interactions
obtained with DDM, simple linear regressions were performed in
order to deﬁne linear functions correlating the data from checker-
board and Etest to the DDM results (Fig. 2). The Etest and
checkerboard variables were linearized by logarithmic conversions.
The population (n) used for this correlation included not only data
from this study but also other synergistic data obtained in parallel
studies between these antibiotics tested and other plant com-
pounds. The strength of the linear association between pairs
of variables was determined by coefﬁcients of determination (R-
square). According to the scheme proposed by Nicodemo et al.
(2004), a strong correlation was found between Etest and DDM (R-
square = 77.4%; P b 0.05; n = 240) and between checkerboard and
DDM (R-square = 71.4%, P b 0.05; n = 380).
The classiﬁcation of each combination was compared between
methods. Agreement between methods was deﬁned as all methodsal agent.
DDM Time-kill assay
ons (IZDa+p − IZDa) ≥ 6 mm ≥2 log10decrease in CFU/mL of
the antibiotic
4 ≤ (IZDa+p − IZDa) b 6 mm log10 decrease ≥1 and b2 in CFU/mL
of the antibiotic
ns (IZDa − IZDa+p) ≥ 6 mm ≥2-log10 increase in CFU/mL of
the antibiotic
ve interactions. a = antibiotic; p = phytochemical.
Fig. 2. Correlation between the DDM results (IZD combination – IZD most active agent)
and the MIC reductions given by checkerboard (A) and by Etest (B).
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1 method displaying disagreement results; and major disagreement
was deﬁned when 2 or more methods display disagreement results.
2.9. Cytotoxicity tests
The cytotoxicity of the alkaloids was evaluated according to ISO/
EN 10993 (part 5) guidelines with somemodiﬁcations (ISO document
10993, 1992). L929 cells (ATCC CCL 1), derived from an immortalized
mouse lung ﬁbroblast cell line and routinely used in in vitro
cytotoxicity assessments, were used. Cells were grown in 175 cm2
culture ﬂasks using Dulbecco’s modiﬁed eagle medium (DMEM;
Sigma) supplemented with 1% of penicillin/streptomycin solution
(Sigma) and 10% of fetal bovine serum (FBS; Biochrome, Matosinhos,
Portugal). The ﬂasks were incubated at 37 °C for 72 h in a 95% air 5%
CO2 atmosphere with 100% humidity. Twenty-four hours before the
cytotoxicity tests starts, cells were trypsinised, seeded in 96-well
microtiter plates at a concentration of 1 × 104 cells per well, and left
to adhere at 37 °C in a 95% air 5% CO2 atmosphere with 100%
humidity. Then, the medium in each well was replaced by 200 μL of
fresh DMEM with the alkaloids at several concentrations (chosen
according to the antimicrobial assays). The alkaloids did not exceed 2%
(v/v) of the well ﬁnal volume. The positive control was performed by
adding fresh medium without any alkaloid and the negative control
by adding DMSO at 2% (v/v). Each condition was performed in 5 wells
and in triplicate. The plates were incubated for 72 h (at 37 °C, in a 95%
air 5% CO2 atmosphere with 100% humidity). Then, the cell viability
was assessed by using the Cell Titer 96® One solution Cell
proliferation Assay Kit (Promega, Madrid, Spain). This assay involves
the bioreduction of the substrate (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxyl-methoxy-phenyl)-2(4-sulfophenyl)-2H tetrazolium) (MTS)
into a brown formazan product by NADPH or NADP produced bydehydrogenase enzymes in metabolically active cells (Baran et al.,
2004).After incubation, the medium with alkaloids was removed and
replaced by 200 μL of a mixture of DMEM without FBS and MTS (1:5
ratio) and incubated at the same conditions for 3 h. The optical density
(OD) of each well was measured at 490 nm using a plate reader
(Molecular Devices, Sunnyvale, USA). From the dose–response curves
obtained, the half maximal inhibitory concentration (IC50) values
were calculated by probit analysis, according to Sebaugh (2011).
2.10. Statistical analysis
For statistical analysis, the in vitro results were analyzed by
Student’s t test using the statistical program SPSS version 19.0
(Statistical Package for the Social Sciences). Statistical calculations
were based on a conﬁdence level ≥95% (P b 0.05), which was
considered statistically signiﬁcant. Relatively to the simple linear
regressions performed correlating the checkerboard and Etest data to
the DDM results, the validation of these linear models was carried out
by F-test. All P values reported were 2-tailed, and values lower than
0.05 were considered signiﬁcant.
3. Results
All alkaloids were assessed for antibacterial activity using the
broth microdilution technique. Only QUIN had antibacterial activity,
with an MIC of 500 mg/L for S. aureus CECT 976. For the other
strains, no MIC was detected for QUIN for the concentrations tested
(until 1500 mg/L). The other alkaloids had no activity against the
strains tested for the same concentrations (data not shown). RES
reacted with the MH broth causing a blank turbidity, which
complicated the detection of its MIC. Therefore, colony counts in
MH agar were performed in order to evaluate the growth of the
bacteria with the increasing concentrations of RES. No growth
reduction was veriﬁed.
TheMICs of the antibiotics alone and in combinationwith alkaloids
obtained by microdilution technique and Etest are shown in Tables 2
and 3, respectively. The agreement between the MICs (only of the
antibiotics) obtained by these 2 methods (within ± 1 log2 dilutions)
was of 75% for TET, 88% for ERY, and only 38% for CIP. The overall level
of agreement was 66.7%. The discrepancy results were caused by
broth MICs higher than Etest MICs. No increase in the MICs of the
antibiotics was obtained in the presence of alkaloids (P N 0.05). Table 4
shows the IZDs obtained by the DDM method for each combinatorial
case. No IZD was obtained with each alkaloid alone (data not shown).
The IZD of each combination was never smaller than that produced by
each drug alone (P N 0.05).
According to the analysis of MICs and IZDs by the susceptibility
breakpoints of the NCCLS/CLSI (2003), the MRSA strains were
classiﬁed as resistant to AMP, OXA, ERY, and CIP and only susceptible
to TET. MSSA strains were classiﬁed as susceptible to all antibiotics,
with exception of AMP. Broth test, Etest, and DDM showed 95%
agreement on these classiﬁcations.
Time-kill assay was only performed for the strains with known
efﬂux pumps (S. aureus SA1199B, XU212, RN4220) since only few
concentrations of the drugs can be tested in each assay. Fig. 3 shows
the log10 increase or decrease in antibacterial activity obtained for
each combination over the single activity of the antibiotic alone. No
CFU reduction was observed with the alkaloids alone for the
concentrations tested (P N 0.05, data not shown). The effect of the
combination between PYR and CIP (at ½ MIC) against S. aureus
SA1199B caused a 2.4 log10 decrease in CFU/mL (with an initial
inoculum of 6.5 ± 0.53 log10 CFU/mL to undetectable levels) after 24 h
when compared with CIP alone. Also, the combination between QUIN
and CIP (at ½ MIC) caused a 1.3 log10 decrease in CFU/mL after the
same time. Tetracycline (at ½ MIC) combined with RES and QUIN
against S. aureus XU212 achieved a log10 reduction of 2.8 and 2.0 in
Table 2
MIC results obtained by checkerboard for the antibiotics alone (control) and in combination with alkaloids against the S. aureus strains tested. Combinations promoting a signiﬁcant
antibiotic MIC reduction (P b 0.05) are in bold.
Checkerboard MICs
Isolates Antib. Control CAF RES PYR THEO QUIN
CECT 976 CIP 1 1 1 1 1 1
TET 0.96 0.96 0.96 0.96 0.96 0.96
ERY 0.24 0.24 0.24 0.06 (4.0) 0.24 0.24
AMP 1.5 1.5 1.5 1.5 1.5 1.5
OXA 0.48 0.48 0.48 0.48 0.48 0.48
SA1199B CIP 128 128 64 (2.0) 64 (2.0) 128 100
XU212 TET 128 128 32 (4.0) 128 128 100
RN4220 ERY 256 256 256 64 (4.0) 256 256
MRSA MJMC001 CIP 256 256 256 256 256 256
TET 0.5 0.5 0.5 0.5 0.5 0.25 (2.0)
ERY 96 96 96 96 96 96
AMP 64 64 64 64 64 64
OXA 128 128 128 128 128 128
MRSA MJMC002 CIP 256 256 256 256 256 256
TET 0.5 0.5 0.25 (2.0) 0.5 0.5 0.25 (2.0)
ERY 96 96 96 96 96 96
AMP 64 64 64 64 64 64
OXA 128 128 128 128 128 128
MRSA MJMC004 CIP 256 256 256 256 256 256
TET 0.5 0.5 0.5 0.5 0.5 0.5
ERY 96 96 96 96 96 96
AMP 64 64 64 64 64 64
OXA 15.6 15.6 15.6 15.6 15.6 15.6
MSSA MJMC003 CIP 0.5 0.5 0.25 (2.0) 0.25 (2.0) 0.5 0.25 (2.0)
TET 2 2 2 1 (2.0) 2 1 (2.0)
ERY 0.5 0.5 0.25 (2.0) 0.13 (4.0) 0.5 0.25 (2.0)
AMP 25 25 3.7 (6.8) 25 25 25
OXA 1 1 1 1 1 1
MSSA MJMC009 CIP 1 1 0.5 (2.0) 0.13 (8.0) 1 0.25 (4.0)
TET 0.5 0.5 0.06 (8.3) 0.25 (2.0) 0.5 0.06 (8.3)
ERY 2 2 2 1 (2.0) 2 1 (2.0)
AMP 10 10 1.5 (6.7) 0.74 (13.5) 10 1.5 (6.7)
OXA 1 1 1 1 1 1
MSSA MJMC010 CIP 1 1 0.13 (7.7) 0.25 (4.0) 1 1
TET 0.5 0.5 0.06 (8.3) 0.5 0.5 0.06 (8.3)
ERY 0.5 0.5 0.5 0.25 (2.0) 0.5 0.25 (2.0)
AMP 10 10 10 10 10 10
OXA 1 1 1 1 1 1
MICs ranged between 2-fold dilutions and the highest value was chosen (n ≥ 3). CAF, PYR, THEO: 500 mg/L; RES, QUIN: 100 mg/L. Fold reductions are given in parentheses.
Table 3
MIC results obtained by Etest for the antibiotics alone (control) and in combination with alkaloids against the S. aureus strains tested. Combinations promoting a signiﬁcant antibiotic
MIC reduction (P b 0.05) are in bold.
Etest MICs
Isolates Antib. Control CAF RES PYR THEO QUIN
CECT 976 CIP 0.064 0.064 0.064 0.064 0.064 0.064
TET 0.38 0.38 0.38 0.38 0.38 0.38
ERY 0.19 0.19 0.19 0.047 (4.0) 0.19 0.19
SA1199B CIP 4 4 2 (2.0) 2 (2.0) 4 0.5 (8.0)
XU212 TET 32 32 12 (2.7) 32 32 16 (2.0)
RN4220 ERY 256 256 256 32 (8.0) 256 256
MRSA MJMC001 CIP N32 N32 N32 N32 N32 N32
TET 0.38 0.38 0.38 0.38 0.38 0.19 (2.0)
ERY 96 96 96 96 96 96
MRSA MJMC002 CIP N32 N32 N32 N32 N32 N32
TET 0.38 0.38 0.19 (2.0) 0.38 0.38 0.19 (2.0)
ERY 96 96 96 96 96 96
MRSA MJMC004 CIP N32 N32 N32 N32 N32 N32
TET 0.38 0.38 0.38 0.38 0.38 0.38
ERY 96 96 96 96 96 96
MSSA MJMC003 CIP 0.19 0.19 0.094 (2.0) 0.094 (2.0) 0.19 0.094 (2.0)
TET 0.38 0.38 0.38 0.38 0.38 0.19(2.0)
ERY 0.19 0.19 0.094 (2.0) 0.047 (4.0) 0.19 0.19
MSSA MJMC009 CIP 0.19 0.19 0.094 (2.0) 0.094 (2.0) 0.19 0.094 (2.0)
TET 0.25 0.25 0.25 0.25 0.25 0.25
ERY 2 2 1 (2.0) 0.5 (4.0) 2 2
MSSA MJMC010 CIP 0.19 0.19 0.047 (4.0) 0.064 (3.0) 0.19 0.19
TET 0.38 0.38 0.064 (6.0) 0.38 0.38 0.25 (1.5)
ERY 0.25 0.25 0.125 (2.0) 0.064 (3.9) 0.25 0.064 (3.9)
MICs ranged between 2-fold dilutions and the highest value was chosen (n ≥ 3).CAF, PYR, THEO: 500 mg/L; RES, QUIN: 100 mg/L. Fold reductions are given in parentheses.
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Table 4
Average of IZDs (mean±SD) produced by the antibiotics alone (control) and in combination with alkaloids. Combinations promoting a signiﬁcant increase (P b 0.05) of the antibiotic
IZD are in bold.
IZD (mm)
Isolates Antib. Control CAF RES PYR THEO QUIN
CECT 976 CIP 33.3 ± 0.6 32.0 ± 0.0 33.3 ± 0.6 32.7 ± 1.3 33.8 ± 1.0 32.7 ± 0.5
TET 23.7 ± 0.6 23.7 ± 0.6 24.3 ± 0.5 23.0 ± 0.0 23.3 ± 0.6 24.0 ± 1.0
ERY 26.3 ± 0.6 26.0 ± 1.0 27.3 ± 0.6 33.0 ± 0.7 27.3 ± 1.2 27.3 ± 0.6
AMP 36.0 ± 1.0 37.7 ± 0.6 45.7 ± 0.6 35.7 ± 0.6 36.7 ± 1.3 42.0 ± 1.0
OXA 39.7 ± 0.6 40.7 ± 0.6 38.3 ± 0.5 38.7 ± 0.6 39.7 ± 0.6 40.7 ± 0.6
SA1199B CIP 13.0 ± 0.0 13.0 ± 1.0 18.0 ± 0.0 17.3 ± 0.6 12.3 ± 0.6 25.0 ± 1.0
XU212 TET 9.0 ± 0.0 9.7 ± 0.6 13.0± 0.0 9.0 ± 0.0 10.0 ± 1.0 10.7 ± 0.6
RN4220 ERY x x x 8.7 ± 0.6 x x
MRSA MJMC001 CIP x x x x x x
TET 26.0 ± 0.0 26.7 ± 1.3 30.0 ± 0.0 26.3 ± 0.5 27.0 ± 1.0 30.7 ± 0.6
ERY 12.7 ± 0.5 12.0 ± 0.0 12.0 ± 0.0 12.0 ± 0.0 12.0 ± 0.0 12.0 ± 0.0
AMP x x x x x x
OXA x x x x x x
MRSA MJMC002 CIP x x x x x x
TET 26.0 ± 0.0 26.0 ± 0.0 28.0 ± 0.0 26.0 ± 0.0 26.8 ± 1.0 28.0 ± 0.0
ERY 12.0 ± 0.0 12.0 ± 0.0 12.0 ± 0.0 12.0 ± 0.0 12.1 ± 0.6 12.0 ± 0.7
AMP x x x x x x
OXA x x x x x x
MRSA MJMC004 CIP x x x x x x
TET 27.0 ± 1.0 26.7 ± 0.6 28.0 ± 0.0 27.0 ± 0.0 27.1 ± 0.6 29.7 ± 0.5
ERY 12.0 ± 0.0 12.0 ± 0.0 12.0 ± 0.0 12.0 ± 0.0 12.0 ± 0.0 12.0 ± 0.0
AMP x x x x x x
OXA x x x x x x
MSSA MJMC003 CIP 36.0 ± 0.0 36.0 ± 0.6 37.0 ± 1.0 40.0 ± 0.0 36.4 ± 1.1 38.0 ± 1.0
TET 35.0 ± 0.6 35.1 ± 0.6 35.0 ± 0.7 41.0 ± 0.0 35.0 ± 0.0 37.0 ± 0.0
ERY 31.0 ± 1.0 31.0 ± 0.0 33.0 ± 1.0 43.0 ± 0.0 31.0 ± 1.0 32.0 ± 1.0
AMP 14.0 ± 1.0 14.0 ± 0.0 14.3 ± 0.6 13.3 ± 0.5 14.0 ± 1.0 15.7 ± 0.5
OXA 21.0 ± 0.0 22.0 ± 0.0 24.0 ± 0.0 21.5 ± 0.6 22.0 ± 0.0 23.0 ± 1.0
MSSA MJMC009 CIP 30.0 ± 1.0 30.0 ± 0.7 38.7 ± 0.6 38.0 ± 0.0 30.3 ± 0.6 40.0 ± 1.0
TET 30.0 ± 0.0 30.0 ± 0.0 35.0 ± 0.0 35.0 ± 0.0 30.1 ± 0.6 35.0 ± 0.0
ERY 27.0 ± 0.7 27.8 ± 1.0 36.0 ± 0.0 35.3 ± 0.6 27.0 ± 0.0 32.0 ± 0.0
AMP 15.0 ± 0.0 16.0 ± 0.0 15.0 ± 0.0 14.3 ± 0.6 15.4 ± 1.1 16.0 ± 0.0
OXA 22.3 ± 0.6 22.0 ± 1.0 23.7 ± 0.6 23.0 ± 1.0 23.0 ± 0.0 22.0 ± 0.0
MSSA MJMC010 CIP 34.7 ± 0.0 35.4 ± 1.1 40.7 ± 0.6 40.7 ± 0.6 35.1 ± 0.6 37.7 ± 0.6
TET 37.0 ± 0.0 37.0 ± 0.0 39.0± 0.6 37.0 ± 0.0 37.0 ± 0.0 40.0 ± 1.0
ERY 31.0 ± 0.0 31.3 ± 0.5 40.0 ± 0.0 33.0 ± 0.7 31.3 ± 0.5 35.0 ± 1.0
AMP 14.0 ± 0.0 14.0 ± 0.0 13.8 ± 1.0 13.5 ± 1.0 14.0 ± 1.0 15.5 ± 0.6
OXA 23.3 ± 0.6 23.0 ± 0.0 23.3 ± 0.5 25.0 ± 0.0 24.0 ± 1.0 24.0 ± 0.7
CAF, PYR, THEO: 500 mg/L; RES, QUIN: 100 mg/L. x = no inhibition zone.
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effect was observed with the addition of alkaloids to ERY against
S. aureus RN4220 (P N 0.05).
Results from each test were classiﬁed based on the interpreta-
tion of an interaction as negative/indifferent/additive/potentiation
and compared between each other. Table 5 presents this compar-
ison only for the combinations that resulted in an additive or a
potentiation interaction for, at least, 1 method. Time-kill assay
results showed 66.7% of agreement when compared with the other
methods for SA1199B, XU212, RN4220 (indeed, this method
disagrees with the others in 5 of the 6 cases as shown in Table 5
with these strains). Agreement between checkerboard, Etest, and
DDM was obtained in 93 of 120 combinatorial cases (77.5%), minor
disagreements in 23 of 120 cases (19.2%), and major disagreements
were found in only 6 of 120 combinations (5.0%). About 106 of 120
cases (87.4%) showed agreement between checkerboard and Etest,
164 of 190 cases (86.3%) between checkerboard and DDM, and 99 of
120 cases (82.5%) demonstrated agreement between Etest and
DDM. Indifference was most common among all three methods,
being found in 157 of 190 combinations (82.6%), considering the
cases showing agreement or minor disagreement. Additive in-
teractions were found in 14 of 190 combinations (7.4%). Potenti-
ating activities were only found in 11 of 190 combinations (5.8%),
also considering both the agreement and minor disagreement cases.
No negative interactions were detected.
Potentiation was observed with: RES (at 100 mg/L) when
combined with TET against XU212 and MSSA10 and with CIP againstMSSA10; PYR (at 500 mg/L) when combined with ERY against strains
CECT976, RN422, and MSSA3 and 9 and with CIP against strains
MSSA9 and 10; and QUIN (at 100 mg/L) when combined with CIP
against SA1199B and MSSA9. Additive interactions were obtained
with: RES combined with CIP against SA1199B, MSSA3, and 9, with
TET against MRSA2, and with ERY against MSSA3; PYR combined
with CIP against SA1199B and MSSA3, and with TET against MSSA9;
and QUIN combined with TET against MRSA1 and 2 and MSSA3, with
CIP against MSSA3, and with ERY against MSSA9 and 10. No effect
was observed with the combination between the β-lactams and
alkaloids. Also, CAF and THEO did not potentiate any antibiotic
against any strain.
To assess the suitability of the tested alkaloids for antimicrobial
therapy, cytotoxicity tests were carried out by MTS tests with L929
cells. The positive growth control produced large amounts of a brown
formazan product after incubation, which is an indicator of normal
metabolism and that cells were able to metabolize MTS. The DMSO
control presented a similar viability to the growth control (P b 0.05)
indicating that this compound (at 2% (v/v)) was not toxic for the cells
(data not shown). From the dose–response curves obtained, IC50
values were calculated by probit analysis (Table 6). QUIN demon-
strates a high toxicity to mammalian cells, being the most toxic
alkaloid (IC50 = 25 ± 2.2 mg/L). The concentration of RES used in the
antimicrobial assays, 100mg/L, was inferior to its IC50 (627± 57mg/L).
The other alkaloids were used at concentrations above their IC50, which
was 352 ± 28 mg/L, 274 ± 18 mg/L, and 100 ± 4.7 mg/L for CAF, PYR,
and THEO, respectively.
Fig. 3. Summary for 24-h time-kill assay results for the combinations between alkaloids and CIP against S. aureus SA1199B (A), TET against S. aureus XU212 (B), and ERY against
S. aureus RN4220 (C). Bars with (a) and (b) are statistically different from the antibiotic controls (P b 0.05 and P b 0.01, respectively).
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There are several evidences of non-antimicrobial molecules that
enhanced the activity of antimicrobial agents (Abreu et al., 2012b).
The combination of bioactive compounds is expected to exert a
synergistic outcome or to reduce possible adverse side effects. Also,
the development of active compounds in conjugation with existing
antibiotics could probably avoid the emergence of resistant variants
that might otherwise arise during treatment (Gibbons et al., 2003;
Olajuyigbe and Afolayan, 2012). Typically, synergy indicates that the
compounds in the mixture act via different mechanisms and/or
targets (Lila and Raskin, 2005). Yet, the combined bioactivity of the
mixture can also be potentiated when the interaction results in
improved solubility, absorption, safety, stability, or bioavailability of
the active principle or a resistance-modifying effect. But is synergism
a valid way to think about agents with no antimicrobial activity that
potentiates antibiotics? Perhaps not, in which case, it would be better
to only consider this as a potentiation.
For detecting RMAs or antibiotic coadjuvants, it is expected to
observe a high inactivation of resistant bacteria when the combina-tion of antibiotic/plant compound is applied and only minor or no
antibacterial activity of the phytochemical. In this study, with
exception of QUIN against S. aureus CECT 976, no alkaloid had
antimicrobial activity. The antibiotic MICs varied depending on the
methodology. The overall agreement between broth and Etest MICs
was 66.7%, which is due to broth MICs higher than Etest MICs. So,
these results demonstrate an apparent increased sensitivity of the
agar testing method over the microdilution assay. In the majority of
studies, the agreement between the MICs of these 2 methods varies
since these test systems measure different interactions between an
antimicrobial agent and a microorganism (Mayrhofer et al., 2008;
Serrano et al., 2003; Szekely et al., 1999; van der Heijden et al., 2007).
Therefore, it is expected that there will be some minor differences
between the systems (Rennie et al., 2012). Despite the minimal
antimicrobial activity observed, several MIC reductions were obtained
with RES, PYR, or QUIN combined with CIP, TET, or ERY. Of all 190
combinations performed in this study, only 5.8% and 7.4% were cases
of potentiation and of additive interaction, respectively, while the
remaining was considered indifferent. No potentiating activity was
obtained against MRSA strains; only additive effects were observed
Table 5
Combinatorial results obtained by checkerboard, Etest, DDM, and time-kill methods with the combination between antibiotics and alkaloids. Potentiation results are in bold.
Isolates Antib. Alkal. Checkerboard Etest DDM Time-kill
CECT 976 ERY PYR 4.0 (P) 4.0 (P) 6.7 (P)
AMP RES NC (I) n.p. 9.7 (P)
QUIN NC (I) n.p. 6.0 (P)
SA1199B CIP RES 2.0 (A) 2.0 (A) 5.0 (A) 0.2 (I)
PYR 2.0 (A) 2.0 (A) 4.3 (A) 2.4 (P)
QUIN 1.3 (I) 8.0 (P) 12.0 (P) 1.3 (A)
XU212 TET RES 4.0 (P) 2.7 (P) 3.0 (I) 2.8 (P)
QUIN 1.3 (I) 2.0 (A/I) 1.4 (I) 2.0 (P)
RN4220 ERY PYR 4.0 (P) 8.0 (P) 8.7 (P) 0.4 (I)
MRSA MJMC001 TET QUIN 2.0 (A) 2.0 (A) 4.7 (A)
MRSA MJMC002 TET RES 2.0 (A) 2.0 (A) 2.0 (I)
QUIN 2.0 (A) 2.0 (A) 2.0 (I)
MSSA MJMC003 CIP RES 2.0 (A) 2.0 (A) 1.0 (I)
PYR 2.0 (A) 2.0 (A) 4.0 (A)
QUIN 2.0 (A) 2.0 (A) 2.0 (I)
TET PYR 2.0 (A/I) NC (I) 6.0 (P)
QUIN 2.0 (A) 2.0 (A) 2.0 (I)
ERY RES 2.0 (A) 2.0 (A) 2.0 (I)
PYR 4.0 (P) 4.0 (P) 12.0 (P)
QUIN 2.0 (A/I) NC (I) NC (I)
AMP RES 6.8 (P) NC (I) 0.3 (I)
MSSA MJMC009 CIP RES 2.0 (A) 2.0 (A) 8.7 (P)
PYR 8.0 (P) 2.0 (A/I) 8.0 (P)
QUIN 4.0 (P) 2.0 (A/I) 10.0 (P)
TET RES 8.3 (P) NC (I) 5.0 (A/I)
PYR 2.0 (A) NC (I) 5.0 (A)
QUIN 8.3 (P) NC (I) 5.0 (A/I)
ERY RES NC (I) 2.0 (A/I) 9.0 (P)
PYR 2.0 (A/I) 4.0 (P) 8.3 (P)
QUIN 2.0 (A) NC (I) 5.0 (A)
AMP RES 6.7 (P) NC (I) NC (I)
PYR 13.5 (P) NC (I) −0.7 (I)
QUIN 6.7 (P) NC (I) 1.0 (I)
MSSA MJMC010 CIP RES 7.7 (P) 4.0 (P) 6.0 (P)
PYR 4.0 (P) 3.0 (P) 6.0 (P)
TET RES 8.3 (P) 6.0 (P) 3.0 (I)
QUIN 8.3 (P) 1.5 (A/I) NC (I)
ERY RES NC (I) 2.9 (A/I) 9.0 (P)
PYR 2.0 (A/I) 3.9 (P) 2.0 (I)
QUIN 2.0 (A) 3.9 (P) 4.0 (A)
Classiﬁcations of the combinations as potentiating (P), additive (A), or indifferent (I) are given in parentheses. Only the additive or potentiating interactions reported in, at least, 1
method were represented. An additive interaction was only accepted and distinguished from indifference when 2 or more methods indicated that same categorical result. PYR: 500
mg/L; RES, QUIN: 100 mg/L. n.p. = not performed; NC = no change.
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MRSA2). In fact, studies suggest that resistant bacteria are persistent
in nature due to the stability of the resistance genes and transfer
elements (Marquez, 2005). Concerning strains SA1199B, XU212, and
RN4220, potentiation was obtained between CIP-QUIN, TET-RES, and
ERY-PYR, respectively.
RES, originally extracted from Rauwolﬁa serpentina, was already
studied by several authors due to its properties as EPI (Aeschlimann
et al., 1999; Gibbons and Udo, 2000; Markham et al., 1999; Schmitz
et al., 1998). In this work, this alkaloid showed a potentiating activity
when combined with TET against XU212 and MSSA10 and with CIP
against MRSA2. Also, additive effects were observed with RES and
these antibiotics against other strains. This fact supports in general
previous studies (Gibbons and Udo, 2000; Gibbons et al., 2003;Table 6
In vitro cytotoxicity of the alkaloids (IC50 values, mg/L) obtained with MTS reduction of
L929 cells (mean ± SD; n ≥ 3).
Alkaloids IC50 (mg/L)
CAF 352 ± 28
RES 627 ± 57
PYR 274 ± 18
THEO 100 ± 4.7
QUIN 25.3 ± 2.2Schmitz et al., 1998). However, only a 2-fold reduction of MIC was
observed between RES and CIP against SA1199B. RES appears to be
involved especially in the inhibition of NorA and also TetK efﬂux
pumps, but other efﬂux pumps may probably be implicated. While
RES had effect on some S. aureus strains, for others, no effect was
observed. This can be associated to the fact that strains could vary in
the extent to which RES is able to block NorA or TetK or, also, due to
the varying rates of transcription of the nor and tetK genes or
differences in the stability of its messenger RNA (Schmitz et al.,
1998). RES was applied at concentrations lower than its IC50, which
shows that RES can be a good candidate to be used as cotherapeutic
agent. The interest on this agent increases when one compares it
cytotoxicity value with those of reference alkaloids used currently for
chemotherapy. Abe et al. (2000) found that the growth of L929 cells
was inhibited by vincristine, in a dose-dependent manner, by 20% at
0.25 mg/L and by 35% at 2.5 mg/L. Rassouli et al. (2011) determined
the IC50 value of vincristine (50 mg/L) and of vinblastine (80 mg/L)
using 5637 cells. The IC50 values of vincristine ranged from 0.4 to 5
mg/L when applied to varied cell lines (Chen et al., 2006).
Pyrrolidine, found naturally in the leaves of tobacco and carrot,
potentiated the activity of ERY against S. aureus RN4220, S. aureus
CECT 976, and MSSA3 and of CIP against strains MSSA9 and 10. To our
knowledge, this compound has never been studied for its synergistic
activity. Further tests regarding its structure–activity relationship
would be necessary in order to conclude about the reason behind the
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results with this compound at 500 mg/L may be an obstacle to its
chemotherapeutic use. It would be necessary to evaluate the pros and
negative effects of this compound.
QUIN occurs naturally in the bark of Cinchona tree, and it is a well-
known compoundwith a long history of use due to their efﬁcacy as an
anti-malaria agent. Despite major toxicity concerns and adverse
reactions among patients, QUIN remains one of the most commonly
used antimalarial for therapy (van Vuuren and Viljoen, 2011).
Moreover, this alkaloid was reported for the inhibition of the invasive
ability of some bacteria, namely, staphylococci, which would protect
the immunocompromised patients of being infected during the
antimalarial treatment (Wolf et al., 2002; 2006). In this study, QUIN
potentiated CIP against SA1199B and MSSA9. Several additive
combinations were also observed with QUIN combined with TET
and ERY.
MSSA strains and, less extensively, SA1199B, XU212, and RN4220
strains showed to be much more amenable to potentiation with the
alkaloids than the MRSA strains. With the aim of ﬁnding new therapy
options in mind, this is not the kind of result one would hope to see.
However, given the high virulence, persistence, and resistance proﬁle
of MRSA, this was expected.
In this study, 4 distinct methods were used to evaluate the
potentiating activity of alkaloids when combined with common
antibiotics. It is not new that experimentation on drug interactions
can lead to opposite conclusions by different methodologies. The
various tests used measure quite distinct effects of antibiotic
interactions against bacteria and use different endpoints (inhibition
or killing) and medium state (broth versus agar) (Bonapace et al.,
2000; Eliopoulos and Eliopoulos, 1988; White et al., 1996). However,
with this strategy, it was obtained a good agreement between
checkerboard, Etest, and DDM (77.5%). Also, the agreements of
87.4% between checkerboard and Etest, 86.3% between checkerboard
and DDM, and 82.5% between Etest and DDMwere also very good. On
the contrary, the agreement of time-kill assay with the other 3
methods was low. In general, the agreements obtained in the
literature are diverse (Bonapace et al., 2000; Cantón et al., 2005;
Lewis et al., 2002;Martin, 2010; Orhan et al., 2005;White et al., 1996).
However, a variety of investigators found disagreement between
checkerboard and time-kill results (Cappelletty and Rybak, 1996;
Chang et al., 2007; Visalli et al., 1988; White et al., 1996).
Regarding the performance of all methods, Etest represents,
apparently, the ideal testing methodology for the clinical microbiol-
ogy laboratory since it is a simple and fast method with excellent
reproducibility. However, it is somewhat expensive. DDM seems to
be as an excellent strategy because it is also very easy to perform, it
has good agreement results with the others methods, and it is much
less expensive. Time-kill and checkerboard methods, despite being
the most widely accepted, have many disadvantages. Time-kill assay
is very laborious if a high number of combinations are required, and
the results are greatly inﬂuenced by differences on the inoculum size
and on the interpretation of the results (because relatively few
antibiotic concentrations are examined) (White et al., 1996). Also,
methods for the interpretation of kill-kinetic studies vary, and
synergy has been deﬁned by some authors as at least a 100-fold
increase in killing at 24 h (Bonapace et al., 2000; Jung et al., 2004;
Kiraz et al., 2009; Mayer and Nagy, 1999), while other authors
consider a 200-fold increase (Guo et al., 2008; Leonard, 2012; Tan
et al., 2011). Relatively to checkerboard, the endpoint (i.e., the
complete inhibition of growth) is a qualitative measure (Tariq et al.,
1995), and the occurrence of synergy appears to be highly dependent
on the method of interpretation (Bonapace et al., 2002). Also, the
reproducibility of checkerboard is hardly the best.
In conclusion, in this study, several plant alkaloids were tested in
combination with common antibiotics in order to ﬁnd potentiating
antimicrobial activities. The use of 4 methods to characterize theactivity of the combinations was advantageous since it allowed to
compare the efﬁcacy of each method and to obtain more guarantees
about the certainty of the potentiating combinations obtained. DDM
had good correlation with the other methods, and it is a low-price,
easy, and fast way of determining synergism between the compounds.
Two compounds were especially highlighted as antibiotic coadju-
vants: RES and PYR. QUIN would be a viable option if not for the high
toxicity of this compound. RES is already known as an EPI for the NorA
and TetK efﬂux pumps. This study supports the results already
obtained by other authors. Furthermore, cytotoxicity values of RES are
favorable, which is a good sign for the possible future development of
cotherapies with this alkaloid in animal models and in vivo tests.
Pyrrolidine showed a capacity for potentiating ERY against S. aureus
RN4220, CECT 976, and MSSA3 and CIP against MSSA9 and 10 strains.
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